Allspring Global Investments Holdings LLC Has $186,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Allspring Global Investments Holdings LLC cut its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 66.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 31,740 shares of the company’s stock after selling 63,034 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Voyager Therapeutics were worth $186,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Armistice Capital LLC lifted its position in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Great Point Partners LLC bought a new stake in shares of Voyager Therapeutics during the second quarter valued at approximately $12,668,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Analyst Ratings Changes

VYGR has been the subject of several research analyst reports. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, October 24th. Wedbush dropped their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $17.43.

Voyager Therapeutics Trading Up 2.5 %

NASDAQ VYGR opened at $7.00 on Monday. Voyager Therapeutics, Inc. has a 12 month low of $5.71 and a 12 month high of $11.72. The stock has a 50-day simple moving average of $6.57 and a 200 day simple moving average of $7.56. The company has a market capitalization of $381.71 million, a PE ratio of 25.00 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. The company had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. During the same period in the prior year, the business posted ($0.51) EPS. As a group, sell-side analysts predict that Voyager Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.